Myelofibrosis epidemiology and demographics: Difference between revisions
(→Age) |
|||
| Line 9: | Line 9: | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.<ref name=epidemiologyofmyelofibrosis1radio1>Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016</ref> | *The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.<ref name=epidemiologyofmyelofibrosis1radio1>Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016</ref> | ||
*In developed countries, the prevalence of myelofibrosis is ranged from 0. | *In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref> | ||
===Incidence=== | |||
*In developed countries, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref> | |||
===Age=== | ===Age=== | ||
Revision as of 20:44, 15 November 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics |
|
Risk calculators and risk factors for Myelofibrosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[1] Males are more commonly affected with myelofibrosis than females. The male to female ratio is approximately 1.5 to 1.[2] Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.[3]
Epidemiology and Demographics
Prevalence
- The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.[1]
- In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.[4]
Incidence
- In developed countries, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.[4]
Age
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[1][5]
Gender
Males are more commonly affected with myelofibrosis than females. The male to female ratio is approximately 1.5 to 1.[2]
Race
Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.[3]
References
- ↑ 1.0 1.1 1.2 Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016
- ↑ 2.0 2.1 Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.
- ↑ 3.0 3.1 Causes. The physician's guide to myelofibrosis 2016. http://nordphysicianguides.org/wp-content/uploads/2012/11/NORD_Physician_Guide_to_Myelofibrosis.pdf. Accessed on March 14, 2016
- ↑ 4.0 4.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
- ↑ Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.